Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy

Acta Ophthalmol. 2018 Aug;96(5):e662-e663. doi: 10.1111/aos.13780. Epub 2018 Apr 19.

Authors

Azu Suzuki¹, Yoji Takano², Yasutaka Ando¹, Junko Ogawa¹, Masahiro Ishida³, Akiyasu Baba⁴, Yutaka Imamura^{1

3}

Affiliations

¹ Department of Ophthalmology, Kitasato Institute Hospital, Kitasato Univeristy, Tokyo, Japan.
² Department of Ophthalmology, Kawasaki Municipal Ida Hospital, Kanagawa, Japan.
³ Department of Ophthalmology, Teikyo University School of Medicine, University Hospital Mizonokuchi, Kanagawa, Japan.
⁴ Department of Cardiology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.

PMID: 29671951
DOI: 10.1111/aos.13780

No abstract available

Publication types

Letter

MeSH terms

Administration, Oral
Central Serous Chorioretinopathy / diagnosis
Central Serous Chorioretinopathy / diagnostic imaging*
Central Serous Chorioretinopathy / drug therapy
Dose-Response Relationship, Drug
Eplerenone
Female
Follow-Up Studies
Humans
Male
Middle Aged
Mineralocorticoid Receptor Antagonists / administration & dosage
Retinal Pigment Epithelium / pathology
Spironolactone / administration & dosage
Spironolactone / analogs & derivatives*
Time Factors
Treatment Outcome

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone
Eplerenone

Grants and funding

Koureisha Ganshikkan Kenkyu Zaidan in Japan